Floatz logo

Vebreltinib

MET Alteration

Apollomics Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the MET Alteration cohort.

Asset / SponsorPhaseRating
Osimertinib
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2CC
Vert-002
Pierre Fabre Medicament
Phase 1/2CC
ans014004
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2CC
plb1004
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2CC

Same molecule, other indications

Vebreltinib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
58 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →